Ulcerative Colitis

Why trials studying Ulcerative Colitis stopped, in this sample of ClinicalTrials.gov.

24 stopped trials with a clear reason; 96% ended for non-scientific reasons.

Trials

• Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
  NCT05539625 · WITHDRAWN · manufacturing supply
  “Unable to secure IMP supply.”
• Study to Investigate Comparative Efficacy, Safety and Immunogenicity Between AVT16 and Entyvio
  NCT06570772 · TERMINATED · funding business
  “The study has been terminated based on Sponsor decision. This decision is not related to any safety concerns associated with the investigational products. It is related to the fact that study will be not required for product dossier submission.”
• Ulcerative Colitis Leukocyte TRAfficking After Treatment With Zeposia: the ULTRAZ Study
  NCT06188637 · WITHDRAWN · funding business
  “Funder decision”
• Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis
  NCT05176366 · TERMINATED · slow accrual
  “Enrollment challenges.”
• Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
  NCT04626947 · TERMINATED · funding business
  “Sponsor's decision”
• Serum Bovine Immunoglobulin (SBI) in Children and Young Adults With Inflammatory Bowel Disease (IBD)
  NCT04223518 · TERMINATED · slow accrual
  “Lack of study participants”
• Curcumin in Pediatric Ulcerative Colitis
  NCT02277223 · WITHDRAWN · slow accrual
  “Difficulty to enroll patients”
• The Role of Secondary Bile Acids in Intestinal Inflammation
  NCT03724175 · TERMINATED · slow accrual
  “Lack of recruitment and funding.”
• Reactive vs. Proactive Pain Control in IBD
  NCT03798405 · TERMINATED · logistics pi
  “COVID-19-related restrictions”
• Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center Study
  NCT03772145 · TERMINATED · slow accrual
  “Futility; recruitment to slow to justify longer study duration”
• Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis
  NCT03616821 · TERMINATED · funding business
  “Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.”
• Infliximab Accelerated Induction in Moderate to Severe Pediatric UC
  NCT03209232 · TERMINATED · slow accrual
  “Difficulty to recruit patients and as high dose infliximab for severe UC is now the rule rather than the exception”
• HMPL004-6599 Phase I Dose-escalating Study
  NCT03597971 · TERMINATED · funding business
  “Sponsor decision”
• A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
  NCT03281304 · TERMINATED · funding business
  “The study terminated early due to business reasons, with the study already meeting its primary objective. The decision to terminate the trial was not based on any safety and/or efficacy concerns.”
• Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction
  NCT02729233 · WITHDRAWN · funding business
  “Funding withdrawn”
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
  NCT02118584 · TERMINATED · funding business
  “The study was terminated due to program discontinuation, based on mixed efficacy results in the parent studies. There were no safety concerns.”
• A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis
  NCT02058524 · TERMINATED · slow accrual
  “Unable to recruit and enroll eligible subjects.”
• Study to Evaluate the Pharmacodynamics and Safety of HGS1025 in Patients With Ulcerative Colitis
  NCT01434576 · WITHDRAWN · funding business
  “Sponsor withdrew study for business reasons”
• Decisional Influences and Inflammatory Bowel Disease (IBD) Patients' Medication Use
  NCT00968721 · TERMINATED · funding business
  “lack of support”
• A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)
  NCT00947674 · TERMINATED · slow accrual
  “short of enrollment”
• Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial
  NCT00553163 · TERMINATED · slow accrual
  “Unable to recruit sufficient numbers of patinets in the time available”
• Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab Study
  NCT00279435 · TERMINATED · funding business
  “company decision based on other studies”
• A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
  NCT00279422 · TERMINATED · futility
  “DMC recommendation, no efficacy”
• Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.
  NCT00259571 · WITHDRAWN · funding business
  “Missing financial sponsorship”

Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.